Major drugmaker loses $27 billion in market value after failed trial
—·2h
Two companies announced on Thursday that the heart disease drug they had been developing failed its Phase III trial.
TickersIIIChannelsstocksCountriesusaCategoriespharma
Open original source ↗Published
7/9/2026, 12:03:00 PM
Fetched
7/9/2026, 12:07:06 PM
Confidence
60 / 100
Relevance
39 / 100
Trust
—
Language
en